Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Adds External R&D Management Unit
by Rick Mullin
May 30, 2005
| A version of this story appeared in
Volume 83, Issue 22
PHARMACEUTICALS
GlaxoSmithKline is expanding its "centers of excellence" framework for research and development with the creation of the Centre of Excellence for External Drug Discovery (CEEDD).
GSK's six current centers of excellence for drug discovery (CEDD) each coordinate in-house research assets on specific therapeutic categories, such as cardiovascular or respiratory disease. CEEDD will work across all therapeutic areas coordinating GSK's research and drug development partnerships. CEEDD, which will be headed by Maxine Gowen, will take charge of collaborations with industry and academic researchers that have been managed under GSK's Alternative Discovery Initiative, according to GSK. It will establish dedicated research groups for each partnership and assign specific goals for developing compounds on each project.
CEEDD will draw on front-end resources of the CEDDs, accessing compounds and targets discovered by GSK for which the firm lacks readily available internal development resources. In addition, the company says CEEDD is intended to give GSK access to alternative scientific and drug discovery approaches through collaborative arrangements with partners.
Gowen, formerly the director of GSK's department of bone and cartilage biology, most recently held the position of president of SR One, the drug firm's venture-capital business (C&EN, Oct. 13, 2003, page 23).
"I am very pleased that Maxine will lead the CEEDD," says Moncef Slaoui, GSK's senior vice president of worldwide business development. "Her established scientific and business acumen will be key to the success."
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter